SCA
KPTI icon

Secor Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Secor Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,463
Closed -$627K – 495
2018
Q4 		$627K Buy
+4,463
New +$753K 0.08% 284
2017
Q2 		– Sell
-4,054
Closed -$781K – 525
2017
Q1 		$781K Sell
4,054
-378
-9% -$60.7K 0.09% 282
2016
Q4 		$625K Buy
+4,432
New +$599K 0.08% 306

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Secor Capital Advisors's KPTI Position: Q1 2019 in Review

Secor Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2019, closing a stake of 4,463 shares — an estimated $627K sold.

Secor Capital Advisors first reported a position in KPTI in Q4 2016 and held it in 3 quarters. The position peaked at $781K in Q1 2017. 108 funds tracked by Wall St. Rank hold KPTI as of Q1 2019.

  • Secor Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 4,463 Karyopharm Therapeutics shares in Q1 2019, an estimated $627K.
  • Secor Capital Advisors first reported a position in Karyopharm Therapeutics in Q4 2016 and held it in 3 quarters.
  • Secor Capital Advisors's Karyopharm Therapeutics position peaked at $781K in Q1 2017.
  • 108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.